Original Article
Brief Report
Fasting Hypoketotic Coma in a Child with Deficiency of Mitochondrial 3-Hydroxy-3-Methylglutaryl-CoA Synthase
N Engl J Med 1997; 337:1203-1207October 23, 1997
- Article
Fasting is accompanied by a decrease in the availability of glucose for energy use in peripheral tissues and, consequently, an increased reliance of these tissues on the availability of ketone bodies and fatty acids for energy. The availability of ketone bodies depends almost exclusively on hepatic ketogenesis. Failure of ketogenesis may occur in patients with any defect of the enzymes associated with the mitochondrial oxidation of fatty acids.1 These defects are typically manifested by hypoglycemia, which results from the inadequate supply of alternative substrate (ketones). Other clinical features are more variable and may include myopathy, cardiomyopathy, hepatocellular damage, and neuropathies. Studies in rats have indicated a pivotal role for mitochondrial 3-hydroxy-3-methylglutaryl–coenzyme A (HMG-CoA) synthase in the control of ketogenesis.2-4
HMG-CoA synthase has cytosolic and mitochondrial forms that, although structurally similar, are controlled by different genes.5 Both forms catalyze the combination of acetoacetyl-CoA and acetyl-CoA to form β-hydroxy-β-methylglutaryl-CoA, which in the cytosol is a precursor of sterols and in the mitochondria is converted to acetoacetate (Figure 1Figure 1
Role of 3-Hydroxy-3-Methylglutaryl-CoA (HMG-CoA) Synthase in Hepatic Mitochondrial Ketogenesis.). During fasting, acetyl-CoA produced by mitochondrial β-oxidation of fatty acids in the liver is largely directed toward the production of ketones, with minimal use of the tricarboxylic acid cycle,6 so that the vast majority of the two-carbon units produced by fatty-acid oxidation are directed through HMG-CoA synthase to the production of ketone bodies.In this report, we describe an 11-year-old boy with deficiency of mitochondrial HMG-CoA synthase. This case report underlines the importance of the enzyme as a control point in ketogenesis and confirms the functional difference between the cytosolic and mitochondrial forms of HMG-CoA synthase.
Case Report
A boy of Chinese descent first presented at six years of age after mild gastroenteritis with poor oral intake for two to three days that culminated in a brief generalized seizure, which left him semicomatose. His blood glucose concentration was 9 mg per deciliter (0.5 mmol per liter), and a urine dipstick test was negative for ketones. He had previously been well and tolerated minor illnesses without difficulty. Physical examination was normal. The child responded within five minutes to intravenous dextrose, with further improvement over the next hour. Blood lactate and plasma ammonia, aminotransferase, and carnitine concentrations were normal, as was urinary excretion of organic acids when measured two days later.
The patient was given a normal diet, and the parents were advised not to allow the boy to go without food for prolonged periods. Subsequently, he continued to tolerate minor illnesses with no difficulty, and on one occasion strenuous exercise for one hour did not provoke increases in serum creatine kinase or cholesterol concentrations. His physical and mental development during the next five years were normal, as were plasma carnitine, creatine kinase, creatinine, cholesterol, and aminotransferase concentrations on several occasions. Plasma alanine and lactate concentrations were normal even during periods of stress, suggesting that gluconeogenesis was normal. There have been no further seizures; the seizure on presentation was attributed to hypoglycemia. The boy's parents are not related, and he has one sister, who is healthy and has never had any symptoms such as his.
Methods
Provocative Tests
At the age of seven the patient fasted for 22 hours. Blood was collected every two to four hours from hour 14 to hour 22 for measurements of blood glucose and plasma free fatty acid and β-hydroxybutyrate concentrations. Urine was collected for organic-acid analysis at the end of the fast. After a 15-hour fast, the boy was given 1.5 g of medium-chain triglycerides per kilogram of body weight orally, and then plasma β-hydroxybutyrate was measured at hourly intervals for 3 hours, blood glucose was measured every 15 to 30 minutes for 3 hours, and urine and plasma were collected for organic-acid analysis at 3 hours. A similar protocol was followed after the child had fasted for 12 hours and was then given long-chain triglycerides in the form of safflower oil (1.5 g per kilogram). The boy's parents gave informed consent for all the diagnostic investigations.
Analyses of Enzymes and Metabolites
HMG-CoA lyase activity in cultured transformed lymphoblasts, plasma and tissue carnitine, plasma nonesterified fatty acids and 3-hydroxybutyrate, and plasma and urine acylcarnitines and organic acids were measured as previously described.7-12 Assays of long-chain, medium-chain, and short-chain acyl-CoA dehydrogenases in skin fibroblasts were kindly performed by Dr. A. Adams (Melbourne, Australia); assays of long-chain and short-chain hydroxyacyl-CoA dehydrogenases, enoyl-CoA hydratase, and thiolases were performed by Dr. R. Wanders (Amsterdam); assays of carnitine palmitoyltransferases I and II were performed by Dr. F. Demaugre (Paris); and a screening test for defective fatty-acid oxidation based on palmitate and myristate oxidation was performed by Drs. B. Wilcken and J. Hammond (Sydney, Australia).13
Liver Biopsy
The boy underwent wedge biopsy of the liver at the age of nine years, with the written informed consent of his parents, for histologic examination and measurement of HMG-CoA synthase activity. Control specimens of normal liver were obtained from two persons who had died accidentally (the interval between death and collection was less than two hours) and from one person who underwent open liver biopsy during an investigation for suspected metabolic disease, which was subsequently ruled out.
HMG-CoA Synthase Activity
HMG-CoA synthase activity was measured in whole homogenates of liver tissue and in cultured skin fibroblasts by radioisotopic modification14 of a coupled enzyme assay.15 The assay measures the conversion of acetyl-CoA to acetoacetate by means of HMG-CoA and therefore depends on the activities of acetoacetyl-CoA thiolase, HMG-CoA synthase, and HMG-CoA lyase. In the liver, 90 percent of acetoacetate is produced in mitochondria.14 Citrate synthase activity was measured in the liver homogenates as a control mitochondrial enzyme to assess sample preservation.16
Results
After fasting for 22 hours, the patient had a blood glucose concentration of 41 mg per deciliter (2.3 mmol per liter) and a plasma β-hydroxybutyrate concentration of 0.2 mmol per liter (normal, >2.0). He rapidly became comatose, waking about 30 minutes after receiving a bolus intravenous injection of dextrose (500 mg per kilogram) followed by a continuous infusion at a rate of 10 mg per kilogram per minute. This response is slower than that expected in children with brief episodes of hypoglycemia, in whom coma usually resolves within minutes.
After the ingestion of long-chain triglycerides, the patient's plasma free fatty-acid concentrations increased appropriately, but plasma β-hydroxybutyrate concentrations remained below 0.15 mmol per liter (normal response, >0.5). The patient's plasma β-hydroxybutyrate concentrations (Table 1Table 1
Plasma Concentrations of 3-Hydroxycarboxylic Acids after the Ingestion of Medium-Chain Triglycerides.) also remained low after the ingestion of medium-chain triglycerides, indicating that enzyme function after the oxidation of long-chain fatty acids, the first step in ketone-body formation, was abnormal. Four hours after the ingestion of medium-chain triglycerides the boy became comatose, with a blood glucose concentration of 50 mg per deciliter (2.8 mmol per liter). He was then given intravenous dextrose (in the same dose as before) and responded in about one hour.Urinary excretion of organic acids was normal on several occasions during minor illnesses and after fasting and the ingestion of long-chain triglycerides. After the ingestion of medium-chain triglycerides plasma concentrations of hydroxy fatty acids, including 3-hydroxyhexanoate and 3-hydroxyoctanoate, increased markedly (Table 1). Urinary excretion of ethyl malonate was slightly elevated (38 μmol per millimole of creatinine), and traces of 3-ketohexanoate were also present. Hydroxy fatty acids were not detected in plasma during fasting, and their presence after the ingestion of medium-chain triglycerides therefore most likely reflects defective metabolism of medium-chain triglycerides, raising the possibility that fatty-acid toxicity contributed to the patient's coma. After the ingestion of long-chain triglycerides, plasma 3-hydroxyhexanoate and 3-hydroxyoctanoate concentrations were 6 and 2 μmol per liter, respectively, as compared with respective base-line values of 4 and less than 2 μmol per liter.
Histologic examination of the liver showed mild fatty infiltration, mainly in the periportal regions, but no other abnormalities. Electron microscopy revealed moderate variation in the size of the mitochondria, and many contained nonspecific crystalline inclusions. The total carnitine content of the liver was 1278 nmol per gram of wet weight (normal, 900 to 1800), and the free carnitine content was 698 nmol per gram of wet weight (normal, approximately 70 percent of the total content). Analysis of blood spots on filter paper by tandem mass spectrometry revealed a normal acylcarnitine profile.
The HMG-CoA synthase activity in the patient's liver was 5 to 20 percent of that in samples of normal liver (Table 2Table 2
Activities of HMG-CoA Synthase and Citrate Synthase in Liver Specimens from a Patient with HMG-CoA Synthase Deficiency and Three Normal Subjects.). In mixing experiments, HMG-CoA synthase activity in combined samples was equal to the sum of the values in samples from the patient and the normal subjects. This finding rules out the possibility that an inhibitor was responsible for the reduced activity in the patient's liver and confirms that the defect was in the rate-limiting step (i.e., at the level of HMG-CoA synthase). Hepatic citrate synthase activity was similar in the patient and the normal subjects. The activities of other enzymes involved in fatty-acid oxidation in fibroblasts were normal.Discussion
The occurrence of episodes of hypoketotic, hypoglycemic coma during fasting in our patient is typical of deficiencies of enzymes involved in mitochondrial fatty-acid oxidation.1 The studies performed while the patient was fasting confirmed that ketogenesis was defective, and the fat-loading studies indicated that the defect was not in the metabolism of long-chain fatty acids. Plasma carnitine concentrations are low in many patients with defects of fatty-acid β-oxidation, with normal values previously having been associated with carnitine palmitoyltransferase I deficiency and multiple mild defects in dehydrogenation. The normal plasma and liver values in our patient, together with the results of the fat-loading tests and the finding of normal urinary excretion of organic acids, raised the suspicion of a fault in the final stages of ketogenesis. Our patient had no evidence of HMG-CoA lyase deficiency, and acetoacetyl-CoA thiolase deficiency typically presents with hyperketosis. Thus, a deficiency of HMG-CoA synthase appeared likely. The patient's hepatic HMG-CoA synthase activity was approximately 10 percent of that in normal liver. This residual activity almost certainly reflected cytosolic HMG-CoA synthase activity, which contributes about 10 percent of the overall HMG-CoA synthase activity in normal liver.17 The results in our patient therefore support the diagnosis of a deficiency of hepatic mitochondrial HMG-CoA synthase activity.
Control of hepatic ketogenesis is exerted by two major regulatory enzymes, carnitine palmitoyltransferase I and mitochondrial HMG-CoA synthase.18 Carnitine palmitoyltransferase I has a clear role in controlling the initiation of β-oxidation and, hence, ketogenesis, but appears to have little influence on later control (down-regulation) of the process.19 HMG-CoA synthase is active in both the initiation and the down-regulation of ketogenesis,2-4 as well as having a specific role in the control of β-oxidation of medium-chain triglycerides. This specific role would explain the sensitivity of our patient to medium-chain triglycerides and the appearance of abnormal metabolites after the ingestion of medium-chain triglycerides. Although the mitochondrial HMG-CoA synthase gene has been sequenced in rats20 and birds,21 the location of the gene in humans is not known.
The diagnosis of mitochondrial HMG-CoA synthase deficiency is not straightforward. Like other defects of fatty-acid oxidation, this condition should be considered in any patient with coma induced by fasting or a life-threatening event from the newborn period through infancy to middle childhood. In particular, this deficiency may possibly contribute to the sudden infant death syndrome and Reye's syndrome. Low levels of HMG-CoA synthase have been identified in lymphocytes, intestine, kidney, testis, and ovary,22,23 but our patient had no symptoms to suggest the involvement of these tissues. HMG-CoA synthase therefore appears to cause symptoms only in relation to its hepatic location, and these symptoms are similar to those that occur in patients with most other defects in fatty-acid oxidation. However, some of these defects involve multiple organs, and the absence of such involvement in the presence of normal plasma carnitine concentrations and normal urinary excretion of organic acids should raise the suspicion of HMG-CoA synthase deficiency. However, the results of diagnostic tests of value in other disorders of fatty-acid oxidation were normal in our patient, and specific diagnosis currently relies on liver-enzyme assay.
The clinical course in our patient confirms the importance of hepatic synthesis of ketones to the maintenance of the energy supply during fasting. The absence of any demonstrable disturbance of cholesterol metabolism underlines the functional distinction between the cytosolic and mitochondrial forms of HMG-CoA synthase. Our patient was asymptomatic except during prolonged fasting. In contrast, patients with deficiency of HMG-CoA lyase, the final enzyme of the ketogenic pathway, typically have more prominent symptoms. This difference could be due to the fact that metabolic stress on pathways of protein metabolism, as well as on those of fatty-acid metabolism, can induce symptoms in the latter condition24 or, possibly, to the variation in acyl-CoA accumulation between the two disorders, the latter being reflected in the relative derangements in carnitine metabolism. Although ketones are thought to be important for the developing brain,25 the normal neurologic development in both our patient and many with HMG-CoA lyase deficiency indicates that ketone synthesis is not essential to brain development as long as prolonged fasting is avoided.
Supported by grants (R01-DK43841 and RR-00240) from the National Institutes of Health.
We are indebted to Dr. D. Millington for performing acylcarnitine analysis, to Drs. R. Wanders and A. Adams for the enzyme assay of fibroblasts, to Dr. C.W. Chow for histopathological analyses, to Dr. F. Demaugre for measuring carnitine palmitoyltransferase activities, to Drs. B. Wilcken and J. Hammond for the oxidation studies of palmitate and myristate, to Mr. H. Tan for performing laparoscopic liver biopsy, to Dr. D. Thorburn for laboratory assistance, and to Ms. D. Francis for dietetic assistance.
Source Information
From the Murdoch Institute, Parkville, Victoria, Australia (G.N.T., E.T.); the Division of Endocrinology and Diabetes, Children's Hospital of Philadelphia, Philadelphia (B.Y.L.H., C.A.S.); and the Department of Biochemistry, Royal Children's Hospital, Parkville, Victoria, Australia (J.J.P.).
Address reprint requests to Dr. Thompson at 96 Kensington Rd., Toorak Gardens, S.A. 5065, Australia.
- References
References
1
Roe CR, Coates PM. Mitochondrial fatty acid oxidation disorders. In: Scriver CR, Beaudet AL, Sly WS, Valle D. The metabolic and molecular bases of inherited disease. 7th ed. Vol. 1. New York: McGraw-Hill, 1995:1501-33.
2
Casals N ,Roca N ,Guerrero M , et al. Regulation of the expression of the mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase gene: its role in the control of ketogenesis. Biochem J 1992;283:261-264
Web of Science | Medline3
Ayte J ,Gil-Gomez G ,Hegardt FG . Methylation of the regulatory region of the mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase gene leads to its transcriptional inactivation. Biochem J 1993;295:807-812
Web of Science | Medline4
Serra D ,Casals N ,Asins G ,Royo T ,Ciudad CJ ,Hegardt FG . Regulation of mitochondrial 3-hydroxy-3-methylglutaryl-coenzyme A synthase protein by starvation, fat feeding, and diabetes. Arch Biochem Biophys 1993;307:40-45
CrossRef | Web of Science | Medline5
Ayte J ,Gil-Gomez G ,Haro D ,Marrero PF ,Hegardt FG . Rat mitochondrial and cytosolic 3-hydroxy-3-methylglutaryl-CoA synthases are encoded by two different genes. Proc Natl Acad Sci U S A 1990;87:3874-3878
CrossRef | Web of Science | Medline6
Des Rosiers C ,David F ,Garneau M ,Brunengraber H . Nonhomogeneous labeling of liver mitochondrial acetyl-CoA. J Biol Chem 1991;266:1574-1578
Web of Science | Medline7
Wysocki SJ ,Hahnel R . 3-Hydroxy-3-methylglutaric aciduria: 3-hydroxy-3-methylglutaryl-coenzyme A lyase levels in leucocytes. Clin Chim Acta 1976;73:373-375
CrossRef | Web of Science | Medline8
Cederblad G ,Lindstedt S . A method for the determination of carnitine in the picomole range. Clin Chim Acta 1972;37:235-243
CrossRef | Web of Science | Medline9
Fourre C ,Rota M ,Vassault A ,Bonnefont JP ,Nicolas A ,Bailly M . Miniaturisation et automatization du dosage du glucose, du pyruvate, du lactate, de l'acetoacetate, du β-hydroxybutyrate, des acides gras nonesterifies sanguins. Acta Pharm Biol Clin 1987;4:420-42310
Millington DS ,Kodo N ,Terada N ,Roe D ,Chace DH . The analysis of diagnostic markers of genetic disorders in human blood and urine using tandem mass spectrometry with liquid SIMS. Int J Mass Spectrom 1991;111:211-216
CrossRef | Web of Science11
Duran M ,Bruinvis L ,Ketting D ,de Klerk JBC ,Wadman SK . Cis-4-decenoic acid in plasma: a characteristic metabolite in medium-chain acyl-CoA dehydrogenase deficiency. Clin Chem 1988;34:548-551
Web of Science | Medline12
Tanaka K ,West-Dull A ,Hine DG ,Lynn TB ,Lowe T . Gas-chromatographic method of analysis for urinary organic acids. II. Description of the procedure, and its application to diagnosis of patients with organic acidurias. Clin Chem 1980;26:1847-1853
Web of Science | Medline13
Manning NJ ,Olpin SE ,Pollitt RJ ,Webley J . A comparison of [9,10-H]palmitic and [9,10-H]myristic acids for the detection of fatty acid oxidation defects in intact cultured fibroblasts. J Inherit Metab Dis 1990;13:58-68
CrossRef | Web of Science | Medline14
Stanley CA ,Gonzales E ,Baker L . Development of hepatic fatty acid oxidation and ketogenesis in the newborn guinea pig. Pediatr Res 1983;17:224-229
Web of Science | Medline15
Williamson DH ,Bates MW ,Krebs HA . Activity and intracellular distribution of enzymes of ketone-body metabolism in rat liver. Biochem J 1968;108:353-361
Web of Science | Medline16
Stanley CA ,Hale DE ,Berry GT ,Deleeuw S ,Boxer J ,Bonnefont J-P . A deficiency of carnitine-acylcarnitine translocase in the inner mitochondrial membrane. N Engl J Med 1992;327:19-23
Full Text | Web of Science | Medline17
Quant PA ,Tubbs PK ,Brand MD . Treatment of rats with glucagon or mannoheptulose increases mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase activity and decreases succinyl-CoA content in liver. Biochem J 1989;262:159-164
Web of Science | Medline18
Guzman M ,Geelen MJ . Regulation of fatty acid oxidation in mammalian liver. Biochim Biophys Acta 1993;1167:227-241
Web of Science | Medline19
Grantham BD ,Zammit VA . Role of carnitine palmitoyltransferase I in the regulation of hepatic ketogenesis during the onset and reversal of chronic diabetes. Biochem J 1988;249:409-414
Web of Science | Medline20
Gil-Gomez G ,Ayte J ,Hegardt FG . The rat mitochondrial 3-hydroxy-3-methylglutaryl-coenzyme-A-synthase gene contains elements that mediate its multihormonal regulation and tissue specificity. Eur J Biochem 1993;213:773-779
CrossRef | Medline21
Kattar-Cooley PA ,Wang HH ,Mende-Mueller LM ,Miziorko HM . Avian liver 3-hydroxy-3-methylglutaryl-CoA synthase: distinct genes encode the cholesterogenic and ketogenic isozymes. Arch Biochem Biophys 1990;283:523-529
CrossRef | Web of Science | Medline22
Curi R ,Williams JF ,Newsholme EA . Formation of ketone bodies by resting lymphocytes. Int J Biochem 1989;21:1133-1136
CrossRef | Medline23
Royo T ,Pedragosa MJ ,Ayte J ,Gil-Gomez G ,Vilaro S ,Hegardt FG . Testis and ovary express the gene for the ketogenic mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase. J Lipid Res 1993;34:1636-1636
Medline24
Thompson GN ,Chalmers RA ,Halliday D . The contribution of protein catabolism to metabolic decompensation in 3-hydroxy-3-methylglutaric aciduria. Eur J Pediatr 1990;149:346-350
CrossRef | Web of Science | Medline25
Williamson DH . Ketone body metabolism during development. Fed Proc 1985;44:2342-2346
Medline
- Citing Articles (16)
Citing Articles
1
Jörn Oliver Sass. (2011) Inborn errors of ketogenesis and ketone body utilization. Journal of Inherited Metabolic Disease
CrossRef2
Terry G. J. Derks, Theo H. van Dijk, Aldo Grefhorst, Jan-Peter Rake, G. Peter A. Smit, Folkert Kuipers, Dirk-Jan Reijngoud. (2008) Inhibition of mitochondrial fatty acid oxidation in vivo only slightly suppresses gluconeogenesis but enhances clearance of glucose in mice. Hepatology 47:3, 1032-1042
CrossRef3
Yuichi Yamazaki, Satoru Kakizaki, Daichi Takizawa, Takeshi Ichikawa, Ken Sato, Hitoshi Takagi, Masatomo Mori. (2008) Interstrain differences in susceptibility to non-alcoholic steatohepatitis. Journal of Gastroenterology and Hepatology 23:2, 276-282
CrossRef4
R. Aledo, C. Mir, R. N. Dalton, C. Turner, J. Pié, F. G. Hegardt, N. Casals, M. P. Champion. (2006) Refining the diagnosis of mitochondrial HMG-CoA synthase deficiency. Journal of Inherited Metabolic Disease 29:1, 207-211
CrossRef5
Simon Edward Olpin. (2004) Implications of impaired ketogenesis in fatty acid oxidation disorders. Prostaglandins, Leukotrienes and Essential Fatty Acids 70:3, 293-308
CrossRef6
Jerry Vockley, Rani H. Singh, David A.H. Whiteman. (2002) Diagnosis and management of defects of mitochondrial β-oxidation. Current Opinion in Clinical Nutrition and Metabolic Care 5:6, 601-609
CrossRef7
Keow G. Sim, Judith Hammond, Bridget Wilcken. (2002) Strategies for the diagnosis of mitochondrial fatty acid β-oxidation disorders. Clinica Chimica Acta 323:1-2, 37-58
CrossRef8
Piero Rinaldo, Dietrich Matern, Michael J. Bennett. (2002) F
ATTY ACID OXIDATION DISORDERS . Annual Review of Physiology 64:1, 477-502
CrossRef9
LUIGI BOUCHARD, MARIE-FRANCE ROBERT, DMITRIY VINAROV, CHARLES A. STANLEY, GEOFFREY N. THOMPSON, ANDREW MORRIS, JAMES V. LEONARD, PATTI QUANT, BETTY Y.L. HSU, AVIHU BONEH, YOUSSEF BOUKAFTANE, LYUDMILA ASHMARINA, SHUPEI WANG, HENRY MIZIORKO, GRANT A. MITCHELL. (2001) Mitochondrial 3-Hydroxy-3-Methylglutaryl-CoA Synthase Deficiency: Clinical Course and Description of Causal Mutations in Two Patients. Pediatric Research 49:3, 326-331
CrossRef10
Piero Rinaldo, Dietrich Matern. (2000) Disorders of fatty acid transport and mitochondrial oxidation. Genetics in Medicine 2:6, 338-344
CrossRef11
Bradley E. Aouizerat, Hooman Allayee, Jackie Bodnar, Kelly L. Krass, Leena Peltonen, Tjerk W. A. de Bruin, Jerome I. Rotter, Aidons J. Lusis. (1999) Novel genes for familial combined hyperlipidemia. Current Opinion in Lipidology 10:2, 113-122
CrossRef12
Piero Rinaldo, Hye-Ran Yoon, Chunli Yu, Kimiyo Raymond, Caterina Tiozzo, Giuseppe Giordano. (1999) Sudden and unexpected neonatal death: A protocol for the postmortem diagnosis of fatty acid oxidation disorders. Seminars in Perinatology 23:2, 204-210
CrossRef13
Al Odaib, Ali, Shneider, Benjamin L., Bennett, Michael J., Pober, Barbara R., Reyes-Mugica, Miguel, Friedman, Amy L., Suchy, Frederick J., Rinaldo, Piero, . (1998) A Defect in the Transport of Long-Chain Fatty Acids Associated with Acute Liver Failure. New England Journal of Medicine 339:24, 1752-1757
Full Text14
Andrew A.M. Morris, Douglass M. Turnbull. (1998) Fatty acid oxidation defects in muscle. Current Opinion in Neurology 11:5, 485-490
CrossRef15
ANDREW A. M. MORRIS, CAROL V. LASCELLES, SIMON E. OLPIN, BRIAN D. LAKE, JAMES V. LEONARD, PATTI A. QUANT. (1998) Hepatic Mitochondrial 3-Hydroxy-3-Methylglutaryl-Coenzyme A Synthase Deficiency. Pediatric Research 44:3, 392-396
CrossRef16
Hugo W. Moser. (1998) Neurometabolic disease. Current Opinion in Neurology 11:2, 91-95
CrossRef
